About Bachem
About Bachem
A global partner for peptide and oligonucleotide development and manufacturing, supporting pharmaceutical and biotechnology companies from early research to commercial supply.
Who we are
Bachem supports pharmaceutical and biotechnology companies across the full lifecycle of peptide and oligonucleotide products — from early development to reliable commercial supply.
Drawing on decades of experience, we combine deep scientific know-how with scalable manufacturing infrastructure. Our integrated development and production capabilities enable partners to translate complex molecules into viable therapies.
What sets Bachem apart
Quality & regulatory excellence
GMP manufacturing built on decades of global regulatory and production experience.
Scientific depth & molecular complexity
Expertise in complex peptides and advancing oligonucleotide capabilities supported by strong analytical know-how.
Integrated development & manufacturing
From early development to commercial supply within one aligned operational framework.
Scalability & reliability
Global infrastructure continuously expanded to support growing demand for TIDES therapies.
Long-term partnerships
Collaborating with pharmaceutical partners across the full product lifecycle.
Leadership, vision and strategy
Bachem is guided by an experienced executive team and governed by a strong board structure that supports sustainable growth, operational reliability, and long-term partnerships.
Our vision is to enable the next generation of TIDES therapies worldwide. Our strategy focuses on disciplined investment in technology, capacity, and global operations to ensure long-term value creation for partners and stakeholders.
Corporate Executive Committee
Related documents
Code of conduct
Statuten / Articles of Association of Bachem Holding AG
Discover Bachem in more detail
Code of Conduct
Bachem’s Code of Conduct defines standards for ethical conduct, compliance, integrity, and responsible actions across all global operations.
Innovation & Technology
Advancing peptide and oligonucleotide technologies through scientific and process innovation.
Sustainability
Sustainability is key to Bachem, and one of its five strategic foundations.
Our journey since 1971
Bachem has grown continuously since its founding in 1971, developing from a small peptide laboratory into a global leader in TIDES manufacturing. Over the years, we have expanded our scientific capabilities and global network through key milestones, including the acquisition of Bachem California (1996) and the integration of Sochinaz SA (2001), strengthening our API manufacturing foundation.
Recent developments reflect our commitment to innovation and scale: we advanced industrial‑scale peptide technologies through our collaboration with GlyTech on Interferon β‑1a (2013), expanded our U.S. presence with the acquisition of the American Peptide Company (2015), and commissioned a modern R&D and small‑series production facility in Bubendorf (2016).
Building on this momentum, we initiated a strategic expansion into oligonucleotide development and manufacturing from 2018 onward, positioning Bachem to meet the accelerating global demand for complex TIDES therapeutics.
Being part of a team that makes a difference?
Working at Bachem is not just a job, it's a chance to contribute to meaningful projects that impact patients lives. We offer a collaborative and supportive work environment where innovation is encouraged & valued.